Search results for "DISCOVERY"

showing 10 items of 4119 documents

2019

PIK3CA-related overgrowth spectrum (PROS) encompasses a range of debilitating conditions defined by asymmetric overgrowth caused by mosaic activating PIK3CA variants. PIK3CA encodes the p110α catalytic subunit of phosphatidylinositol-3-kinase (PI3K), a critical transducer of growth factor signaling. As mTOR mediates the growth-promoting actions of PI3K, we hypothesized that the mTOR inhibitor sirolimus would slow pathological overgrowth. Thirty-nine participants with PROS and progressive overgrowth were enrolled into open-label studies across three centers, and results were pooled. For the primary outcome, tissue volumes at affected and unaffected sites were measured by dual energy X-ray ab…

0301 basic medicinemedicine.medical_specialtybusiness.industrySirolimus therapyLow doseDiscovery and development of mTOR inhibitorsGastroenterology03 medical and health sciences030104 developmental biology0302 clinical medicinePrimary outcome030220 oncology & carcinogenesisSirolimusInternal medicinemedicineAsymmetric overgrowthbusinessAdverse effectPathologicalGenetics (clinical)medicine.drugGenetics in Medicine
researchProduct

Modulation of Heart Rate by Acute or Chronic Aerobic Exercise. Potential Effects on Blood Pressure Control.

2017

It was initially assumed that heart rate and arterial blood pressure were modulated by normal respiration and muscle contraction. The arterial baroreflex, an inverse relationship between blood pressure and heart rate, was later reported. Nonetheless, it was then assumed that those responses involved vagal modulation. We summarize available evidence on the modulation of heart rate by acute or chronic aerobic exercise as well as its potential implications on blood pressure (BP) control. Numerous studies have tried to clarify whether aerobic exercise modifies neurally-mediated vasoconstriction, but they report contradictory results. In view of these incongruities, the aim of this narrative rev…

0301 basic medicinemedicine.medical_specialtyhypertensionBlood Pressureexercise; arterial baroreflex; autonomous nervous system; blood pressure; heart rate; hypertension.Disease03 medical and health sciences0302 clinical medicineHeart Rateautonomous nervous systemInternal medicineDrug DiscoveryHeart rateRespirationHeart rate variabilityMedicineAerobic exerciseAnimalsHumansCardiovascular fitnessExercisePharmacologybusiness.industryarterial baroreflex030229 sport sciences030104 developmental biologyBlood pressureCardiologymedicine.symptombusinessVasoconstrictionCurrent pharmaceutical design
researchProduct

Impact of Communicative and Informative Strategies on Influenza Vaccination Adherence and Absenteeism from Work of Health Care Professionals Working …

2019

Every year, about 20% of health care workers (HCWs) acquire influenza, continuing to work and encouraging virus spreading. Influenza vaccination coverage rates and absenteeism from work among HCWs of the University Hospital (UH) of Palermo were analyzed before and after the implementation of several initiatives in order to increase HCWs&rsquo

0301 basic medicinemedicine.medical_specialtyinformative strategieshealth care facilities manpower and serviceseducation030106 microbiologyImmunologylcsh:MedicineArticlehealth care workers03 medical and health sciences0302 clinical medicineDrug DiscoveryHealth caremedicineHealth care workerPharmacology (medical)030212 general & internal medicineWeb sitePharmacologyvaccination coveragebusiness.industrylcsh:Rvirus diseasesMean ageCommunication campaignUniversity hospitalinfluenza vaccinationVaccinationInfectious DiseasesWork (electrical)Vaccination coverageFamily medicineInformative strategieAbsenteeismcommunication campaignsbusinessVaccines
researchProduct

Management of Ponatinib in Patients with Chronic Myeloid Leukemia with Cardiovascular Risk Factors

2019

Cardiovascular (CV) adverse events are considered common complications of ponatinib treatment. Recently, it has been demonstrated that ponatinib dose reductions in definite settings can obtain optimal responses and lower ponatinib-related CV events. In this study, we describe the management of 5 patients with chronic myeloid leukemia treated with ponatinib, from second to fourth line of tyrosine kinase inhibitor therapy, carrying high pre-ponatinib CV risk, who obtained optimal molecular response and developed no CV adverse event during follow-up. Among these 5 patients, 2 had diagnosis of ischemic heart disease and underwent percutaneous angioplasty, 2 had type 2 diabetes and arterial hype…

0301 basic medicinemedicine.medical_specialtymedicine.drug_class030106 microbiologyCardiovascular risk factorsType 2 diabetesDiseaseTyrosine-kinase inhibitorSettore MED/15 - Malattie Del Sangue03 medical and health scienceschemistry.chemical_compound0302 clinical medicineInternal medicineDrug DiscoverymedicinePharmacology (medical)In patientAdverse effectPharmacologybusiness.industryPonatinibChronic myeloid leukemiaMyeloid leukemiaGeneral Medicinemedicine.diseaseCardiovascular riskInfectious DiseasesOncologychemistry030220 oncology & carcinogenesisPonatinibbusiness
researchProduct

Immunotherapeutic properties of chemotherapy

2017

IF 5.363; International audience; Impressive remissions driven by immunological checkpoint blockade in cancer patients have prompted the scientific community to investigate afresh the crosstalk between cancer cells and the patient's immune system. Preclinical and clinical studies have highlighted that the anticancer efficacy of some conventional chemotherapeutics is based on their ability to restore anticancer immune responses. The current challenge is to understand and circumvent immune resistance mechanisms to chemo- and immunotherapies to design relevant immunotherapy and chemotherapy combinations. In this review, we will summarize which immunological processes are involved in the antica…

0301 basic medicinemedicine.medical_treatmentAntineoplastic Agents[SDV.CAN]Life Sciences [q-bio]/Cancer[ SDV.CAN ] Life Sciences [q-bio]/Cancer03 medical and health sciencesImmune systemNeoplasmsDrug DiscoveryAnimalsHumansMedicineCytotoxicityPharmacologyChemotherapybusiness.industryImmunogenicityImmunotherapyImmune checkpointGastrointestinal Microbiome3. Good healthBlockade030104 developmental biologyImmunologyCancer cellCancer researchImmunotherapybusinessCurrent Opinion in Pharmacology
researchProduct

Synthesis and antiproliferative mechanism of action of pyrrolo[3′,2′:6,7] cyclohepta[1,2-d]pyrimidin-2-amines as singlet oxygen photosensitizers

2016

A new series of pyrrolo[3′,2′:6,7]cyclohepta[1,2-d]pyrimidin-2-amines, was conveniently prepared using a versatile and high yielding multistep sequence. A good number of derivatives was obtained and the cellular photocytotoxicity was evaluated in vitro against three different human tumor cell lines with EC50 (0.08–4.96 μM) values reaching the nanomolar level. Selected compounds were investigated by laser flash photolysis. The most photocytotoxic derivative, exhibiting a fairly long-lived triplet state (τ ∼ 7 μs) and absorbance in the UV–Vis, was tested in the photo-oxidations of 9,10-anthracenedipropionic acid (ADPA) by singlet oxygen. The photosentizing properties are responsible for the c…

0301 basic medicinemedicine.medical_treatmentPhotodynamic therapyChemistry Techniques SyntheticAntiproliferative activityPhotochemistry01 natural sciencesPhotodynamic therapychemistry.chemical_compound7]cyclohepta[1Drug DiscoveryTriplet stateAmineschemistry.chemical_classificationPhotosensitizing AgentsCell DeathSinglet OxygenChemistrySinglet oxygenGeneral MedicineAntiproliferative activity; Photodynamic therapy; Photosensitizing agents; Pyrrolo[3′; 2′:6; 7]cyclohepta[1; 2-d]pyrimidin-2-amines; Reactive oxygen species; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyPyrrolo[3′2′:67]cyclohepta[12-d]pyrimidin-2-amineSettore ING-IND/22 - Scienza E Tecnologia Dei Materiali2-d]pyrimidin-2-aminesFlash photolysisReactive oxygen specieKineticsAntineoplastic AgentsAbsorbance03 medical and health sciencesCell Line TumormedicineHumansPyrrolo[3′Cell ProliferationPharmacologyReactive oxygen speciesPhotosensitizing agentPhotolysis010405 organic chemistry2′:6Drug Discovery3003 Pharmaceutical SciencePhotodissociationOrganic ChemistryCombinatorial chemistrySettore CHIM/08 - Chimica Farmaceutica0104 chemical sciencesAntiproliferative activity; Photodynamic therapy; Photosensitizing agents; Pyrrolo[3′2′:67]cyclohepta[12-d]pyrimidin-2-amines; Reactive oxygen species; Drug Discovery3003 Pharmaceutical Science; Organic Chemistry; PharmacologyKinetics030104 developmental biologyDrug DesignReactive oxygen species
researchProduct

Immunogenicity of a Fully Synthetic MUC1 Glycopeptide Antitumor Vaccine Enhanced by Poly(I:C) as a TLR3-Activating Adjuvant.

2017

Fully synthetic MUC1 glycopeptide antitumor vaccines have a precisely specified structure and induce a targeted immune response without suppression of the immune response when using an immunogenic carrier protein. However, tumor-associated aberrantly glycosylated MUC1 glycopeptides are endogenous structures, “self-antigens”, that exhibit only low immunogenicity. To overcome this obstacle, a fully synthetic MUC1 glycopeptide antitumor vaccine was combined with poly(inosinic acid:cytidylic acid), poly(I:C), as a structurally defined Toll-like receptor 3 (TLR3)-activating adjuvant. This vaccine preparation elicited extraordinary titers of IgG antibodies which strongly bound human breast cancer…

0301 basic medicinemedicine.medical_treatmentchemical and pharmacologic phenomenaBiochemistryCancer Vaccines03 medical and health sciencesMice0302 clinical medicineImmune systemCancer immunotherapyAdjuvants ImmunologicDrug DiscoverymedicineAnimalsHumansGeneral Pharmacology Toxicology and PharmaceuticsMUC1PharmacologyVaccines SyntheticbiologyChemistryImmunogenicityOrganic ChemistryMucin-1GlycopeptidesDendritic CellsVirologyGlycopeptideToll-Like Receptor 3030104 developmental biologyPoly I-C030220 oncology & carcinogenesisTLR3biology.proteinMolecular MedicineAntibodyAdjuvantChemMedChem
researchProduct

Therapeutic Potential of AntagomiR-23b for Treating Myotonic Dystrophy

2020

Myotonic dystrophy type 1 (DM1) is a chronically debilitating, rare genetic disease that originates from an expansion of a noncoding CTG repeat in the dystrophia myotonica protein kinase (DMPK) gene. The expansion becomes pathogenic when DMPK transcripts contain 50 or more repetitions due to the sequestration of the muscleblind-like (MBNL) family of proteins. Depletion of MBNLs causes alterations in splicing patterns in transcripts that contribute to clinical symptoms such as myotonia and muscle weakness and wasting. We previously found that microRNA (miR)-23b directly regulates MBNL1 in DM1 myoblasts and mice and that antisense technology (“antagomiRs”) blocking this microRNA (miRNA) boost…

0301 basic medicinemusculoskeletal diseasescongenital hereditary and neonatal diseases and abnormalitiesMyotonic dystrophyArticleantagomiR03 medical and health scienceschemistry.chemical_compound0302 clinical medicineDrug DiscoverymicroRNAMedicineMBNL1AntagomirProtein kinase AmiRNAmyotonic dystrophybusiness.industrylcsh:RM1-950Muscle weaknessmedicine.diseaseMyotoniaMbnl1030104 developmental biologylcsh:Therapeutics. Pharmacologychemistry030220 oncology & carcinogenesisRNA splicingCancer researchHSALR miceMolecular Medicinemedicine.symptomDM1antisense oligonucleotidesbusinessMolecular Therapy: Nucleic Acids
researchProduct

Proteomics Reveals the Potential Protective Mechanism of Hydrogen Sulfide on Retinal Ganglion Cells in an Ischemia/Reperfusion Injury Animal Model

2020

Glaucoma is the leading cause of irreversible blindness and is characterized by progressive retinal ganglion cell (RGC) degeneration. Hydrogen sulfide (H2S) is a potent neurotransmitter and has been proven to protect RGCs against glaucomatous injury in vitro and in vivo. This study is to provide an overall insight of H2S&rsquo

0301 basic medicineneuronal apoptosisgenetic structuresQuantitative proteomicshydrogen sulfidePharmaceutical Sciencelcsh:Medicinelcsh:RS1-441PharmacologyProteomicsRetinal ganglionArticlelabel-free mass spectrometrylcsh:Pharmacy and materia medica03 medical and health scienceschemistry.chemical_compound0302 clinical medicinemitochondrial functionIn vivoDrug DiscoverymedicineRetinaChemistrylcsh:RRetinalmedicine.diseaseequipment and supplieseye diseases030104 developmental biologymedicine.anatomical_structureglaucomaRetinal ganglion cellMolecular Medicinesense organsReperfusion injurysignalling pathways030217 neurology & neurosurgeryPharmaceuticals
researchProduct

Off-Target-Based Design of Selective HIV-1 PROTEASE Inhibitors

2021

The approval of the first HIV-1 protease inhibitors (HIV-1 PRIs) marked a fundamental step in the control of AIDS, and this class of agents still represents the mainstay therapy for this illness. Despite the undisputed benefits, the necessary lifelong treatment led to numerous severe side-effects (metabolic syndrome, hepatotoxicity, diabetes, etc.). The HIV-1 PRIs are capable of interacting with “secondary” targets (off-targets) characterized by different biological activities from that of HIV-1 protease. In this scenario, the in-silico techniques undoubtedly contributed to the design of new small molecules with well-fitting selectivity against the main target, analyzing possible undesirabl…

0301 basic medicineon/off-targetsProtein ConformationComputer sciencemedicine.medical_treatmentHIV InfectionsLigands01 natural sciencesHIV ProteaseHIV-1 proteaseCatalytic DomainDrug DiscoveryBiology (General)DRUDITSpectroscopyMolecular StructurebiologyGeneral MedicineResearch processSmall moleculeComputer Science ApplicationsMolecular Docking SimulationChemistryligand-structure basedQH301-705.5NCI databaseComputational biologyArticleCatalysisInorganic ChemistryStructure-Activity Relationshipmolecular descriptors03 medical and health sciencesHIV-1 proteasemedicineHumansComputer SimulationPhysical and Theoretical ChemistryQD1-999Molecular BiologyVirtual screeningProteaseOrganic ChemistryHIV Protease Inhibitorsmolecular dockingvirtual screening0104 chemical sciences010404 medicinal & biomolecular chemistry030104 developmental biologyDrug DesignHIV-1biology.proteinInternational Journal of Molecular Sciences
researchProduct